Melanotan II

Overview

Melanotan II is a synthetic cyclic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH), originally developed at the University of Arizona in the 1980s as a potential sunless tanning agent. It acts on melanocortin receptors (MC1R through MC5R) with relatively non-selective activity, meaning it triggers multiple physiological pathways beyond pigmentation — including appetite suppression and sexual arousal, the latter of which led to the development of the related compound bremelanotide (PT-141).

Melanotan II has never been approved by the FDA or any other major regulatory authority for human use. Despite this, it has gained widespread use in unregulated markets, particularly in the tanning and bodybuilding communities. Multiple regulatory agencies globally have issued warnings about its use.

Research context

Early research on Melanotan II focused on its ability to stimulate melanogenesis (the production of melanin pigment in the skin) without UV exposure. Clinical studies conducted at the University of Arizona in the 1990s confirmed that subcutaneous Melanotan II administration could induce skin darkening in human subjects. Unexpected sexual side effects observed during these trials led to the development of bremelanotide, a refined derivative with more selective activity at MC3R and MC4R.

Research areas that have been explored in academic and preclinical settings include melanogenesis and skin pigmentation, sexual function and arousal pathways, appetite regulation and energy homeostasis, and lipid metabolism. However, the broad receptor activity of Melanotan II means that its effects are diffuse and difficult to control, which is one reason it was not advanced through regulatory approval pathways. No large-scale, well-controlled clinical trials exist for Melanotan II in any therapeutic indication.

Safety and regulatory framing

Not approved by FDA or any major authority; FDA Category 2 compounding restriction; multiple regulatory warnings issued

Melanotan II is not approved by the FDA or any other major regulatory authority for any human use. Multiple agencies — including the FDA, the Australian Therapeutic Goods Administration (TGA), and European regulatory bodies — have issued warnings about unapproved Melanotan products, citing risks including uncontrolled changes in moles and skin pigmentation, nausea, facial flushing, and cardiovascular effects, as well as unknown long-term safety implications for melanocyte-active compounds.

Melanotan II is listed on the FDA's Category 2 bulk drug substances list, restricting its use in compounding. Products available from online sources are unregulated and not subject to quality or purity standards. Readers should consult a licensed healthcare provider and be aware that using unapproved substances carries inherent risk.

References

1. Dorr RT, et al. "Effects of Superpotent Melanotropic Peptides in a Pilot Phase I Clinical Study." Life Sciences (1996) ↗
   Life Sciences
2. Hadley ME. "Discovery That a Melanocortin Regulates Sexual Functions in Male and Female Humans." Peptides (2005) ↗
   Peptides
3. TGA (Australia): Melanotan-I and Melanotan-II Safety Advisory ↗
   Therapeutic Goods Administration
4. FDA Warning: Unapproved Tanning Products ↗
   FDA.gov